We are advancing an off-the-shelf, cryopreserved, allogeneic induced pluripotent stem cell (iPSC cardiac cell replacement therapy engineered to restore and strengthen heart muscle tissue that is lost during acute and chronic heart failure. Heart failure is the leading cause of death and our mission is to develop and commercialize a first-in-class medicines that reverses the condition. The company brings together experts in heart regeneration, a collaboration with a leading clinical institutions, and a broad technology platform.